Drug Information of Lasmiditan and Its Effectiveness for Maigraine
Migraine is the leading cause of disability in people under 50 years of age and the second highest cause of disability worldwide with significant impact on the daily lives of patients and their families, 50-200mg lasmiditan is a serotonin (5-HT) 1F receptor agonist new class of medication needed for treatment of migraine, A latest drug with recent studies showns to be efficacious and safe for the prevention of migraine in adults, Lasmiditan was more effective than placebo for the acute treatment of migraine in patients concurrently using migraine preventive medications. Lasmiditan efficacy and safety measures were similar for patients using and not using preventive medications.
2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
3. Steiner TJ, Stovner LJ, Vos T et al (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19:17.2018/02/23. https://doi.org/10.1186/s10194-018-0846-2.
4. Collaborators GDaIIaP (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259. 2017/09/19. https://doi.org/10.1 016/S0140-6736(17)32154-2.
5. Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349. 2007/ 01/31. https://doi.org/10.1212/01.wnl.0000252808.97649.21
6. Silberstein SD, Holland S, Freitag F et al (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78: 1337–1345. 2012/04/25. https://doi.org/10.1212/WNL.0b013e3182535d20
7. Silberstein SD (2015) Preventive Migraine Treatment. Continuum (Minneap Minn) 21:973–989. 2015/08/08. https://doi.org/10.1212/CON. 0000000000000199
8. Evers S, Afra J, Frese A et al (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16:968–981. 2009/08/28. https://doi.org/10.1111/j.1468-1331.2009.02748.x
9. Kline GS. Imitrex: Highlights of Prescribing Information, https://www. accessdata.fda.gov/drugsatfda_docs/label/2012/020132s024s026lbl.pdf (2017, Accessed 10 Mar 2019)
10. Nelson DL, Phebus LA, Johnson KW et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30: 1159–1169. 2010/09/22. https://doi.org/10.1177/0333102410370873
11. Tfelt-Hansen PC. History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia. 2010;30(7):780-792.
12. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174-182.
13. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.
14. Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555-567.
15. Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48(8):856-866.
16. Dodick DW. Migraine. Lancet. 2018;391(10127):1315-1330.
17. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol.2015;14(1):65-80.
18. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193.
19. Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77:281.
20. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54.
21. Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):274-290.
22. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084-1088.
23. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26.
24. Bernice Kuca et al Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study Neurology 2018;91:e2222-e2232
25. Loo et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. The Journal of Headache and Pain (2019) 20:84
26. Deborah Tepper MD, FAHS Lasmiditan for the acute treatment of migraine First published: 31 May 2020 https://doi.org/10.1111/head.13798
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).